According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

Curanex Pharmaceuticals (CURX) has filed for a proposed $10M initial public offering. According to an SEC filing, Curanex is ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets ...

CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class ... of its Investigational New Drug (IND) application ...

today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseasesKT-621 is expected ...

(RTTNews) - Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion ...